Prostate Cancer最新文献

{"title":"Determinants of the Cost of Illness in Iranian Prostate Cancer Patients.","authors":"Ramin Ravangard, Khosro Keshavarz, Mozhgan Seif, Shahryar Zeighami, Abdosaleh Jafari, Faride Sadat Jalali","doi":"10.1155/proc/2149782","DOIUrl":"https://doi.org/10.1155/proc/2149782","url":null,"abstract":"<p><strong>Background: </strong>Prostate cancer (PCa) ranks as the fourth most prevalent form of cancer overall and imposes a substantial financial burden on individuals and communities. Given information on the costs of this disease and the factors influencing them, the present study analyzed factors affecting the costs of medical and nonmedical services for patients with PCa in southern Iran.</p><p><strong>Methods: </strong>Factors affecting the cost of PCa were identified through a scoping review of international databases (ISI Web of Science, Scopus, PubMed, ProQuest, Magiran, and SID) and consultation with PCa experts. Subsequently, data on 254 PCa patients were collected between March 2020 and March 2022 using a two-stage stratified random sampling method. Patients were randomly selected from the provincial Cancer Registry Center lists within strata defined by healthcare catchment areas. Multiple regression analysis using SPSS 13.0 was employed to determine the factors influencing costs.</p><p><strong>Results: </strong>The findings from the multiple regression analysis indicated that premature mortality, grade, and monthly income (all <i>p</i> value < 0.001) were important factors affecting PCa patients' costs.</p><p><strong>Conclusions: </strong>In line with the results, implementing low-cost screening systems for early detection and effective treatment of PCa at all income levels, and directing targeted subsidies to the health sector, especially to low-income patients, can help reduce costs for PCa patients.</p>","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2026 ","pages":"2149782"},"PeriodicalIF":2.0,"publicationDate":"2026-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13080342/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147699602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of Tumor Microenvironmental Acidity on Bicalutamide Sensitivity in Prostate Cancer Cells.","authors":"Pedram Golmohammadi, Idris Haghani, Iman Menbari Oskouie, Rahil Mashhadi, Ahmadreza Rezaeian, Seyed Mohammad Kazem Aghamir","doi":"10.1155/proc/4321914","DOIUrl":"https://doi.org/10.1155/proc/4321914","url":null,"abstract":"<p><strong>Background: </strong>Prostate cancer is the second most commonly diagnosed cancer worldwide. Although androgen deprivation therapy initially demonstrates clinical benefit, disease relapse with more aggressive phenotypes frequently occurs. The acidic tumor microenvironment in solid tumors may alter drug responsiveness. This study investigates how extracellular pH influences the cytotoxic effects of bicalutamide in human prostate cancer cell lines.</p><p><strong>Methods: </strong>PC3 and LNCaP cells were exposed to bicalutamide at varying concentrations at pH 7.4 and pH 6.8. IC50 values were determined using the MTT assay. Cell migration, apoptosis, and cell cycle distribution were evaluated by wound-healing assay, annexin V/PI staining, and DNA content analysis, respectively. The expression of <i>BAX</i>, <i>BCL2</i>, <i>E-cadherin</i>, <i>N-cadherin</i>, <i>SNAI1</i>, <i>AR</i>, and <i>VEGF-C</i> was quantified by qPCR.</p><p><strong>Results: </strong>Bicalutamide (140 μg/mL) reduced PC3 cell viability to 39.62% at pH 7.4 compared with 51.36% at pH 6.8. In LNCaP cells, viability declined to 33.64% at pH 7.4% and 56.09% at pH 6.8. Treated PC3 cells exhibited significantly greater migration at pH 6.8 (<i>p</i> < 0.01). Early apoptosis in treated LNCaP cells was significantly reduced at pH 6.8 (<i>p</i> < 0.001). Both cell lines demonstrated enhanced S phase accumulation and reduced G1-phase distribution at pH 6.8. The <i>BAX</i>/<i>BCL2</i> ratio was significantly decreased at pH 6.8, indicating the suppression of proapoptotic signaling. Additionally, genes associated with epithelial-mesenchymal transition (EMT) were upregulated, and <i>VEGF-C</i> and <i>AR</i> expression increased at pH 6.8 (<i>p</i> < 0.05).</p><p><strong>Conclusion: </strong>The efficacy of bicalutamide in prostate cancer cells is significantly influenced by extracellular pH. The drug exerts stronger cytotoxic, antimigratory, and proapoptotic effects at physiological pH (7.4) compared with acidic conditions (6.8).</p>","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2026 ","pages":"4321914"},"PeriodicalIF":2.0,"publicationDate":"2026-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13051789/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147633575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Treatment Patterns Before and After Metastatic Castration-Resistant Prostate Cancer in Japan: Retrospective Analysis Using a Hospital-Based, Multicenter Database.","authors":"Masaki Shiota, Linghua Xu, Tomoyo Oguri, Masayuki Tanaka","doi":"10.1155/proc/9964591","DOIUrl":"10.1155/proc/9964591","url":null,"abstract":"<p><strong>Background: </strong>Although treatment options for metastatic castration-resistant prostate cancer (mCRPC) have been increasing since 2014, the actual treatment sequences of each drug in clinical practice in Japan have only been reported in a limited number of patients and facilities. The primary objective of this database study was to investigate the general situation and the transition of prior and post-mCRPC treatments.</p><p><strong>Methods: </strong>Using Medical Data Vision's medical record database across Japan, patients diagnosed with mCRPC from January 2015 to December 2022 based on defined criteria were extracted. Treatment sequences before and after mCRPC diagnosis were analyzed.</p><p><strong>Results: </strong>Analysis of 4967 patients revealed that the most common pretreatment for mCRPC was classical vintage hormone therapy (77.1%), followed by androgen receptor signaling inhibitors (ARSI), including enzalutamide (7.8%) and abiraterone (7.4%). The most common treatments for first-line mCRPC were enzalutamide (43.1%), abiraterone (28.3%), and docetaxel (10.7%). When the treatment prior to mCRPC was ARSI, docetaxel was the most common first-line treatment for mCRPC, but another ARSI that had not been used as treatment prior to mCRPC was also selected as first-line mCRPC treatment at a similar rate to docetaxel. Regarding annual changes, the proportion of vintage hormone therapy for mCRPC has been decreasing annually, and there has been a trend to replace it with ARSIs.</p><p><strong>Conclusion: </strong>In terms of the treatment sequence for mCRPC in Japan, vintage hormone therapy was the most common pretreatment for mCRPC, and ARSIs were the most common first-line treatments for mCRPC.</p>","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2026 ","pages":"9964591"},"PeriodicalIF":2.0,"publicationDate":"2026-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12964489/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147378303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlating Histological Results and Total Serum Levels of the Prostate-Specific Antigen Among Patients in Southwestern Uganda.","authors":"Saphurah Nabaasa, Marvin Mwesigwa Mutakooha, Lawrence Amadile, Charles Nkubi Bagenda, Jolly Lydia Ninsiima, Abraham Birungi, Raymond Atwine, Hassan Wasswa, Richard Kasadha, Tibenderana Lauben, Frank Ssedyabane","doi":"10.1155/proc/9924021","DOIUrl":"10.1155/proc/9924021","url":null,"abstract":"<p><strong>Background: </strong>Both healthy and malignant prostate tissues express the glycoprotein marker known as prostate-specific antigen (PSA). When checking for prostate lesions, serum total PSA levels are a major factor. However, the exact levels to rely on are not explicit.</p><p><strong>Objective: </strong>To ascertain the relationship between histopathological findings and serum levels of the PSA in patients in southwest Uganda.</p><p><strong>Methods: </strong>This cross-sectional study involved 71 participants in southwestern Uganda from January to July 2023, who underwent histological examinations. Blood samples were taken off for total serum PSA level measurement. Stained formalin-fixed paraffin-embedded sections were examined. Histological results and PSA levels were correlated using Spearman's correlation coefficient.</p><p><strong>Results: </strong>The study involved 74 participants with an average age of 74.20 ± 9.40 years and average Gleason score of 7.73 ± 1.04. Only 1/71 (1.41%) had prostatic intraepithelial neoplasia (PIN), 36/71 (50.70%) had benign prostate hyperplasia (BPH), and 34/71 (47.89%) had prostate adenocarcinoma (PAC). A significant correlation was observed between PSA levels above 100 ng/mL (<i>p</i> = 0.001, rho = 0.5955) and prostate cancer and between PSA levels up to 20 ng/mL (<i>p</i> = 0.010, rho = 0.03033). AUC of 0.85 (95% CI: 0.77-0.94) showed good predictive power of the test. PSA optimal cut off was 103.4 ng/mL, at sensitivity of 68% and specificity of 92% with maximum Youden index (J): 0.595.</p><p><strong>Conclusion: </strong>There was a significant correlation between BPH with PSA levels up to 20 ng/mL and above 100 ng/mL for prostate adenocarcinoma. In some of the cases, however, total serum PSA levels were high for BPH and low for prostate adenocarcinoma. PSA test usefulness cannot be nullified, but its accuracy and specificity have to be ascertained in order to increase its reliability. Future researches are argued to focus more on how to refine PSA-based diagnostics through identifying any underlying unknown hereditary factors and probably better biomarkers that could be influencing PSA levels. With this, dependability increases and unnecessary biopsing reduces, thus alleviating anxiety in patients and probably their caregivers.</p><p><strong>Contributions of this study: </strong>The study provides additional insights into the importance and clarity of total serum PSA levels in prostate screening and diagnosis.</p>","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2026 ","pages":"9924021"},"PeriodicalIF":2.0,"publicationDate":"2026-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12932906/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147309519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Change in Clinical Management of Localized Prostate Cancer Patients at a Tertiary Medical Center as a Result of SARS-CoV-2 (COVID-19).","authors":"Alexander Yaney, Jonathan E Schoenhals, Yevgeniya Gokun, Andrew Stevens, Jack Wang, Jessica Aduwo, Ahmad Shabsigh, Shawn Dason, Akshay Sood, Evan Thomas, Jacob Eckstein, Russell Palm, Rebekah Young, Dayssy Alexandra Diaz Pardo, Douglas Martin, Shang-Jui Wang","doi":"10.1155/proc/9996270","DOIUrl":"10.1155/proc/9996270","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;At the height of the COVID-19 pandemic, healthcare utilization among cancer patients, including those with prostate cancer, was limited due to inadequate healthcare resources and concern for disease transmission among patients and medical personnel. While publications with treatment recommendations during the pandemic exist, there is limited real-life data comparing prostate cancer management pre-COVID to during the pandemic.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;The primary aim of this study is to determine the effect of the COVID-19 pandemic on prostate cancer management at a tertiary medical center by comparing patients receiving treatment preceding the pandemic to those receiving treatment during the height of the pandemic.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;Prostate cancer patients treated with definitive intent (surgery, definitive radiation (RT), or salvage RT) in 2019-2020 were retrospectively reviewed. Analysis was performed with the following timeframes: pre-COVID as 1/3/19 to 2/28/20 and COVID as 3/1/20 to 9/30/20. Time-to-treatment (TT) for surgery and definitive RT was defined from the date of diagnosis (biopsy or decision to treat if active surveillance) to the date of surgery or RT start, respectively. TT for salvage RT was defined as the date of PSA failure to RT start. Descriptive statistics such as medians and interquartile ranges (IQRs) were reported for continuous variables, while frequency counts and percents were reported for categorical variables. Chi-squared tests (Fisher's exact when appropriate) along with Wilcoxon rank sum tests were used to compare two timeframes. Two adjusted binary logistic regressions assessed the associations of NCCN risk groups, as well as grade group (GG), on the outcome of receipt of treatment during COVID compared to those in pre-COVID timeframes.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;This study sample included 565 prostate cancer patients treated with surgery (&lt;i&gt;n&lt;/i&gt; = 303), definitive RT (&lt;i&gt;n&lt;/i&gt; = 151), or salvage RT (&lt;i&gt;n&lt;/i&gt; = 111). There was a statistically significant difference in TT by timeframe for all patients (median 111 days pre-COVID v 126.5 days COVID, &lt;i&gt;p&lt;/i&gt; = 0.007). For patients who received definitive or salvage RT with ADT, there were significant differences in time from ADT initiation to treatment start between pre-COVID vs. COVID (definitive RT: median 78 days v 147 days, &lt;i&gt;p&lt;/i&gt; = 0.001; salvage RT: median 67 days v 84 days, &lt;i&gt;p&lt;/i&gt; = 0.004). A significantly higher proportion of patients received ADT prior to surgery in the COVID cohort compared to those in pre-COVID (9.8% v 0.5%, &lt;i&gt;p&lt;/i&gt; &lt; 0.001). Patients with clinically more aggressive prostate cancer had higher odds of being treated in the COVID timeframe (HR or VHR, adjusted OR [aOR] 1.62, 95% CI: 1.02-2.55).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;The COVID-19 pandemic changed prostate cancer management in various ways including longer TT, prolonged time from ADT initiation to RT, increased ut","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2026 ","pages":"9996270"},"PeriodicalIF":2.0,"publicationDate":"2026-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12808921/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145998900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reliability of Negative Prostate MRI for Biopsy Decision-Making in the Male Han Chinese Population.","authors":"Fangming Wang, Yan Zhang, Meng Fu, Yuzhe Tang, Haifeng Song, Gang Zhang, Boxing Su, Jianxing Li","doi":"10.1155/proc/1399482","DOIUrl":"10.1155/proc/1399482","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Multiparametric magnetic resonance imaging (mpMRI) has been widely utilized in clinical practice for identifying clinically significant prostate cancer (csPCa). Although mpMRI demonstrates a pooled negative predictive value (NPV) of 90%, additional clinical parameters require evaluation to enhance this metric specifically for the Chinese population-given the rising incidence of PCa in China, as well as ethnic differences in average prostate volume (PV) and chronic prostatitis prevalence that may impact mpMRI's diagnostic performance.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;A retrospective analysis was conducted on 543 patients who underwent transrectal ultrasound-guided prostate biopsy at Beijing Tsinghua Changgung Hospital between November 2014 and March 2025. After applying exclusion criteria, 412 patients were enrolled, all of whom had completed prebiopsy mpMRI within 1 month prior to biopsy. Patients were stratified into four groups based on the results of MRI examination and the pathological outcomes of biopsy: MRI (-) PCa (-), MRI (+) PCa (-), MRI (-) PCa (+), and MRI (+) PCa (+) groups. Multivariate logistic regression analyses were used to assess the odd ratios (ORs) of potential predictors for csPCa, comparing the MRI (-) PCa (+) and MRI (-) PCa (-) groups. Receiver operating characteristic curves were generated to analyze the predictive values of total PSA (tPSA), free PSA (fPSA), free-to-total (f/t) PSA, PV, PSA density (PSAD), and adjusted PSAD (PSAD&lt;sup&gt;adj&lt;/sup&gt;, defined as PSAD × weight) for csPCa in patients with negative MRI.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;The patient distribution was as follows: MRI (-) PCa (-) group: 27.9% (115/412), MRI (+) PCa (-) group: 36.9% (152/412), MRI (-) PCa (+) group: 2.4% (10/412), and MRI (+) PCa (+) group: 32.8% (135/412). The NPV of MRI for csPCa was 92%. Multivariate analyses indicated that PV was negatively associated with the presence of csPCa (OR = 0.940, 95% CI: 0.896-0.986, &lt;i&gt;p&lt;/i&gt; = 0.012), while PSAD and PSAD&lt;sup&gt;adj&lt;/sup&gt; were positively associated with csPCa occurrence (OR = 10.288, 95% CI: 1.569-67.46, &lt;i&gt;p&lt;/i&gt; = 0.015; OR = 1.027, 95% CI: 1.001-1.053, &lt;i&gt;p&lt;/i&gt; = 0.043, respectively). For MRI-negative patients, PV &gt; 55.25 mL (sensitivity = 100%, specificity = 63.2%), PSAD &lt; 0.100 ng/mL&lt;sup&gt;2&lt;/sup&gt; (sensitivity = 100%, specificity = 25.4%), or PSAD&lt;sup&gt;adj&lt;/sup&gt; &lt; 7.24 ng/mL (sensitivity = 100%, specificity = 28.1%) enhanced MRI's NPV to 100%, while PSAD &lt; 0.205 ng/mL&lt;sup&gt;2&lt;/sup&gt; (sensitivity = 77.8%, specificity = 71.9%) and PSAD&lt;sup&gt;adj&lt;/sup&gt; &lt; 24.97 ng/mL (sensitivity = 55.6%, specificity = 90.4%) improved NPV to 97.6% and 92.6%, respectively.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;In Chinese men with negative prostate MRIs, PV &gt; 55.25 mL, PSAD &lt; 0.100 ng/mL&lt;sup&gt;2&lt;/sup&gt;, or PSAD&lt;sup&gt;adj&lt;/sup&gt; &lt; 7.24 ng/mL may elevate mpMRI's NPV from 92% to 100%, enabling safe avoidance of unnecessary biopsies. Prospective multicenter validation is required to confirm these find","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2026 ","pages":"1399482"},"PeriodicalIF":2.0,"publicationDate":"2026-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12798065/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145970905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inhibition of Growth and Induction of Apoptosis of Human Prostate Cancer Cells by Enzymatic Blockage of Kallikreins.","authors":"Fabienne Lehner, Souzan Salemi, Christopher Millan, Christoph Kündig, Daniel Eberli","doi":"10.1155/proc/7871208","DOIUrl":"10.1155/proc/7871208","url":null,"abstract":"<p><strong>Background: </strong>Most therapy options for castration-resistant prostate cancer (CRPCa) target the androgen axis. Human kallikrein-related peptidase (KLK) 2, a serine protease, is a downstream target gene of the androgen receptor (AR) involved in cancer progression, but also known to have an AR-independent function. Tissue KLKs, especially KLK2, are promising targets for therapy in advanced PCa because of their high PCa specificity and their correlation to the rising cancer grade and stage. By inhibition with the recombinant protease inhibitor MDPK67b targeting KLK2 and other trypsin-like KLKs including KLK4 and KLK14, we investigated the antitumor response and the influence on AR downstream target genes with MDPK67b in PCa cell lines in vitro.</p><p><strong>Methods: </strong>Human PCa cells were cultured in a charcoal-stripped media and treated with MDPK67b (0.75 mg/mL). Cell viability was measured by CellTiter-Glo luminescent assay, cell death by flow cytometry. Gene analysis of AR, PSA, and PSMA was performed by qPCR. Correlating protein levels were evaluated by immunoblotting and confirmed by immunocytochemical staining.</p><p><strong>Results: </strong>Treatment with 0.75 mg/mL MDPK67b led to a reduction of cell proliferation of 40% by day 5 in androgen-sensitive LNCaP cells. Immunostaining confirmed the decrease in cell proliferation by antibody labeling of Ki-67. Treatment induced apoptosis, which was visible by flow cytometry of annexin V in LNCaP cells. Further, MDPK67b induced a reduction in AR and PSA gene and protein expression but upregulated PSMA, a target for PCa imaging and therapy.</p><p><strong>Conclusion: </strong>Treatment with MDPK67b demonstrates a significant antitumor effect by relevant reduction in cell proliferation and upregulation of apoptosis in LNCaP cells. Blockage of secreted KLKs can downregulate the AR and thereby influence its downstream target genes like PSA and PSMA. Upregulation of PSMA can lead to a theranostic, that is, therapeutic and diagnostic, advantage in clinics in a CR setting. Therefore, inhibition of KLKs represents a promising and AR-independent approach to treat advanced and CRPCa.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov ID: NCT04644770.</p>","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2026 ","pages":"7871208"},"PeriodicalIF":2.0,"publicationDate":"2026-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12791160/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145966625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cellular Immunotherapy for Prostate Cancer: Lessons Learned From 15 Years of Sipuleucel-T.","authors":"Neal D Shore, Emmanuel S Antonarakis, Jason Hafron, Kelvin A Moses, Christopher Pieczonka, Benjamin Lowentritt, Nadeem Sheikh, Daniel J George, Tanya Barauskas Dorff","doi":"10.1155/proc/9766669","DOIUrl":"10.1155/proc/9766669","url":null,"abstract":"<p><p>The first cellular cancer immunotherapy, sipuleucel-T, was approved for metastatic castration-resistant prostate cancer (mCRPC) patients 15 years ago. Since then, the therapeutic landscape of advanced prostate cancer has significantly evolved. Sipuleucel-T is a personalized, autologous immunotherapy that activates the patient's immune system to target prostatic acid phosphatase (PAP)-expressing tumor cells and has demonstrated survival benefit in patients with nonopioid requiring mCRPC. Subsequent clinical trials and abundant real-world data have provided further evidence of this novel immunotherapy's clinical benefit for patients with mCRPC, as well as demonstrating the numerous immune and biologic responses that sipuleucel-T induces. These data have also identified patient-specific factors associated with longer survival, including race, baseline disease burden, and treatment-induced immune responses. Despite the addition of multiple life-prolonging therapeutic modalities now available to treat patients with mCRPC, the mechanism of action of sipuleucel-T remains unique for patients with advanced prostate cancer. Therefore, maximizing the appropriate clinical utilization of sipuleucel-T in patients with mCRPC within current treatment paradigms is essential.</p>","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2025 ","pages":"9766669"},"PeriodicalIF":2.0,"publicationDate":"2025-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12767674/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145912803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Racial Disparities in the Prescribing of Guideline-Recommended Medications for Metastatic Prostate Cancer: A Retrospective Cohort Study.","authors":"J N Stein, A M Deal, H Winslow, K Morgan, H Muthukrishnan, Y E Whang, M Charlot","doi":"10.1155/proc/6500084","DOIUrl":"10.1155/proc/6500084","url":null,"abstract":"<p><strong>Background: </strong>Prostate cancer is the second leading cause of cancer death among men, with a disproportionate burden on Black men. Racial disparities in care delivery for early-stage disease are well documented but less is known about racial gaps in advanced prostate cancer care, a stage where effective therapies can prolong life for years. We sought to evaluate potential treatment disparities among Black and White men with metastatic prostate cancer.</p><p><strong>Methods: </strong>We performed a retrospective cohort study of patients with metastatic prostate cancer receiving treatment at a large public tertiary care health system between 2015 and 2020 using electronic health record data. We estimated the prevalence ratio (PR) of being prescribed each of the recommended treatment options for metastatic prostate cancer as per National Comprehensive Care Network guidelines, including androgen receptor pathway inhibitors (ARPIs) and other antiandrogens, chemotherapy, and bone protection, comparing Black men to White men.</p><p><strong>Results: </strong>We identified 1166 patients with metastatic prostate cancer treated with androgen deprivation therapy (ADT); 370 (32%) were Black. Prescribing of systemic treatments did not differ by race, notably including ARPI (PR: 0.98 95% CI: 0.98-1.1, <i>p</i>=0.8). About 30% of both Black and White patients interacted with our patient navigation team, a group of oncology nurses focused on ensuring patients receive recommended care.</p><p><strong>Conclusions: </strong>In a large public tertiary care health system, we did not observe racial disparities in the prescribing of guideline-recommended therapies for metastatic prostate cancer. High rates of insurance, a robust patient navigation program, and a well-developed pharmacy assistance program may have helped mitigate racial disparities in care. Future studies should prospectively evaluate the delivery of prostate cancer therapies across health systems and the influence of navigation and pharmacy assistance programs.</p>","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2025 ","pages":"6500084"},"PeriodicalIF":2.0,"publicationDate":"2025-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12674856/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145678465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MRI-Determined Tumor Contact Area as a Predictor of Pathological Extraprostatic Extension in Clinical T2 Prostate Cancer.","authors":"Masashi Tsujimoto, Yuta Inoue, Hideto Taga, Yumiko Saito, Masatomo Kaneko, Masatsugu Miyashita, Takeshi Yamada, Yasuhiro Yamada, Takashi Ueda, Atsuko Fujihara, Takumi Shiraishi, Masayoshi Okumi, Fumiya Hongo, Eiichi Konishi, Kaori Yamada, Kei Yamada, Osamu Ukimura","doi":"10.1155/proc/9165949","DOIUrl":"10.1155/proc/9165949","url":null,"abstract":"<p><strong>Objectives: </strong>To assess the validity of magnetic resonance imaging-determined tumor contact area (MRI-TCA) as a predictive factor for pathological extraprostatic extension (EPE) in cT2N0M0 prostate cancer patients.</p><p><strong>Methods: </strong>We retrospectively analyzed 72 cT2N0M0 prostate cancer patients who underwent multiparametric MRI (mpMRI) followed by robot-assisted laparoscopic prostatectomy (RARP) between February 2014 and April 2021. Patients whose MRI-based index lesion did not match the pathological specimens were excluded. MRI-TCA was approximated using an elliptical shape and calculated by two different methods: MRI-TCA1: Calculated using the tumor contact length (TCL) in the axial plane and the longer TCL in either the sagittal or coronal plane, capturing tumor dimensions across two planes. MRI-TCA2: Calculated using the TCL in the axial plane and tumor thickness derived from MRI slice data, reflecting the tumor's contact area within the MRI volume. We compared postoperative prostate-specific antigen (PSA) recurrence-free survival by stratifying patients based on the optimal thresholds of MRI-TCL, MRI-TCA1, MRI-TCA2, pathological-TCL, and pathological-TCA.</p><p><strong>Results: </strong>Sixteen patients (22.2%) were pathologically positive for EPE. MRI-TCL, MRI-TCA1, and MRI-TCA2 were significantly greater in patients with EPE-positive (EPE+) tumors than in those with EPE-negative (EPE-) tumors (<i>p</i> < 0.0001, <i>p</i> < 0.0001, and <i>p</i> = 0.0026, respectively). No statistically significant differences were found between MRI-TCL and MRI-TCA1 (<i>p</i> = 0.914) or between MRI-TCL and MRI-TCA2 (<i>p</i> = 0.112) in predicting pathological EPE. A significant difference in postoperative PSA recurrence rate was observed in the stratified analysis based on pathological-TCA (<i>p</i> = 0.022).</p><p><strong>Conclusion: </strong>Both MRI-TCA1 and MRI-TCA2 are clinically accessible and effective parameters for predicting pathological EPE in cT2N0M0 prostate cancer patients. However, neither method demonstrated clear superiority over MRI-TCL. Pathological-TCA was shown to be a significant predictor of both pathological EPE and postoperative PSA recurrence.</p>","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2025 ","pages":"9165949"},"PeriodicalIF":2.0,"publicationDate":"2025-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12580032/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145438995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}